Previous studies in our laboratory have found that Se-Met treatment for 12 weeks significantly reduces the cognitive ability of 3xTg-AD mice, reduces Aβ deposition and tau and phosphorylated tau levels, and alleviates oxidative stress and synaptic damage (Zhang et al., 2016, 2017a,b). The gene discussed is MAPT; the disease is Alzheimer disease.